Comments of Clinical and Microbiological Experience with Daptomycin in Chroni...CrimsonpublishersCJMI
Comments of Clinical and Microbiological Experience with Daptomycin in Chronic Osteomyelitis Treatment by Marcano-Lozada Marcel in Cohesive Journal of Microbiology & Infectious Disease
This document discusses the clinical development of monoclonal antibody therapies for cancer treatment. It focuses on five FDA-approved antibodies - rituximab, trastuzumab, bevacizumab, cetuximab, and panitumumab. The document summarizes the clinical trials that led to the approval of rituximab for treating lymphoma, including early phase trials showing efficacy as a single agent and a pivotal trial demonstrating an overall response rate of 48%. It also discusses the mechanisms of action of antibody cancer therapies and opportunities and challenges for developing such therapies in China.
This document summarizes recent developments in molecular targeted therapies for head and neck cancer. It discusses two primary strategies - blocking EGFR signaling and angiogenesis pathways. Epidermal growth factor receptor (EGFR) is overexpressed in many head and neck cancers and associated with poorer outcomes. Cetuximab, an anti-EGFR monoclonal antibody, has shown efficacy in combination with radiation for locally advanced disease and in extending survival when added to chemotherapy for metastatic disease. Other targeted agents discussed include tyrosine kinase inhibitors and anti-angiogenic drugs.
This presentation focuses on appropriate selection of antibiotics in the ICU and discusses different strategies to optimize this selection with the aim to decrease resistance and improve appropriateness.
THERAPEUTIC POTENTIAL OF ANGIOGENESIS INHIBITOR MIXTURES IN CANCER TREATMENT,...ANCA MARIA CIMPEAN
ABSTRACT
It is generally understood that improvement of cancer therapies is achieved by the combination of drugs. This approach will improve efficacy, while toxicity and the risk for drug resistance may be decreased. In this review, the efforts on combining drugs for the treatment of two tumor types is highlighted, followed by a description of the challenges that are faced in designing optimal combination therapies.
This document summarizes Ebsa Bushura's senior seminar presentation on using mycobacterium metabolic pathways as drug targets. It discusses several key metabolic pathways in mycobacteria, such as mycobactin biosynthesis, peptidoglycan biosynthesis, and polyketide sugar unit biosynthesis, that are unique to the pathogen and could be targeted by drugs. It also mentions pathways involved in virulence and persistence, such as the glyoxylate bypass, that represent potential drug targets. The document reviews current approaches to identifying essential genes and those involved in persistence as potential novel anti-tuberculosis drug targets.
Nicholas Nicou completed a 9-month internship at the INSERM research center in Dijon, France, working on tumoral resistance and the link between lipid metabolism abnormalities and chemotherapy resistance. His research focused on the effects of various anticancer drugs on the lipid metabolism in chemoresistant tumoral cells. During his internship, he used techniques like cytotoxicity tests, apoptosis tests, and analyzed the impact of drugs on lipid metabolism and phospholipid biosynthesis through molecular biology experiments and immunofluorescence. His supervisor appreciated his motivation, work ethic, intellectual curiosity, and ability to integrate well into the research team.
This document summarizes a keynote address about biosimilars and biotechnological medicines. It begins with statements that the speaker has received funding from various pharmaceutical companies but does not work for them. It then discusses that biotechnological medicines like proteins are much larger than conventional drugs. Biosimilars are similar but not generic versions of innovative biologics. The document outlines differences between biosimilars and intended copies, and concludes that biosimilars require their own clinical data to demonstrate similar efficacy and safety, while intended copies were approved without such regulations.
Comments of Clinical and Microbiological Experience with Daptomycin in Chroni...CrimsonpublishersCJMI
Comments of Clinical and Microbiological Experience with Daptomycin in Chronic Osteomyelitis Treatment by Marcano-Lozada Marcel in Cohesive Journal of Microbiology & Infectious Disease
This document discusses the clinical development of monoclonal antibody therapies for cancer treatment. It focuses on five FDA-approved antibodies - rituximab, trastuzumab, bevacizumab, cetuximab, and panitumumab. The document summarizes the clinical trials that led to the approval of rituximab for treating lymphoma, including early phase trials showing efficacy as a single agent and a pivotal trial demonstrating an overall response rate of 48%. It also discusses the mechanisms of action of antibody cancer therapies and opportunities and challenges for developing such therapies in China.
This document summarizes recent developments in molecular targeted therapies for head and neck cancer. It discusses two primary strategies - blocking EGFR signaling and angiogenesis pathways. Epidermal growth factor receptor (EGFR) is overexpressed in many head and neck cancers and associated with poorer outcomes. Cetuximab, an anti-EGFR monoclonal antibody, has shown efficacy in combination with radiation for locally advanced disease and in extending survival when added to chemotherapy for metastatic disease. Other targeted agents discussed include tyrosine kinase inhibitors and anti-angiogenic drugs.
This presentation focuses on appropriate selection of antibiotics in the ICU and discusses different strategies to optimize this selection with the aim to decrease resistance and improve appropriateness.
THERAPEUTIC POTENTIAL OF ANGIOGENESIS INHIBITOR MIXTURES IN CANCER TREATMENT,...ANCA MARIA CIMPEAN
ABSTRACT
It is generally understood that improvement of cancer therapies is achieved by the combination of drugs. This approach will improve efficacy, while toxicity and the risk for drug resistance may be decreased. In this review, the efforts on combining drugs for the treatment of two tumor types is highlighted, followed by a description of the challenges that are faced in designing optimal combination therapies.
This document summarizes Ebsa Bushura's senior seminar presentation on using mycobacterium metabolic pathways as drug targets. It discusses several key metabolic pathways in mycobacteria, such as mycobactin biosynthesis, peptidoglycan biosynthesis, and polyketide sugar unit biosynthesis, that are unique to the pathogen and could be targeted by drugs. It also mentions pathways involved in virulence and persistence, such as the glyoxylate bypass, that represent potential drug targets. The document reviews current approaches to identifying essential genes and those involved in persistence as potential novel anti-tuberculosis drug targets.
Nicholas Nicou completed a 9-month internship at the INSERM research center in Dijon, France, working on tumoral resistance and the link between lipid metabolism abnormalities and chemotherapy resistance. His research focused on the effects of various anticancer drugs on the lipid metabolism in chemoresistant tumoral cells. During his internship, he used techniques like cytotoxicity tests, apoptosis tests, and analyzed the impact of drugs on lipid metabolism and phospholipid biosynthesis through molecular biology experiments and immunofluorescence. His supervisor appreciated his motivation, work ethic, intellectual curiosity, and ability to integrate well into the research team.
This document summarizes a keynote address about biosimilars and biotechnological medicines. It begins with statements that the speaker has received funding from various pharmaceutical companies but does not work for them. It then discusses that biotechnological medicines like proteins are much larger than conventional drugs. Biosimilars are similar but not generic versions of innovative biologics. The document outlines differences between biosimilars and intended copies, and concludes that biosimilars require their own clinical data to demonstrate similar efficacy and safety, while intended copies were approved without such regulations.
Cancer Chemoprevention and Molecular Targeting Drug Delivery for CancerSukriti Singh
This document discusses cancer chemoprevention and molecular targeting for drug delivery in cancer treatment. It defines chemoprevention as using agents to reverse, suppress or prevent cancer development. Molecular targeting delivers medication selectively to target tissues to improve efficacy and reduce side effects. Various targeting strategies and carrier systems are described for achieving targeted delivery of chemopreventive and chemotherapeutic agents, including passive, active, ligand-mediated and physical targeting using nanoparticles, liposomes, dendrimers and other carriers. The advantages and challenges of targeted drug delivery systems for cancer are also summarized.
The document discusses recent advances in biosimilars and their future prospects. It begins with an abstract about a student's seminar presentation on personalized medicine and pharmacogenomics. The contents section lists topics like what biosimilars are, literature reviews on the use of targeted drugs and clinical trials, the need for and advantages of personalized medicine, and case studies on using genetic testing to target lung cancer treatments. It explores how pharmacogenomics can optimize drug responses based on a patient's genetics and discusses patents and the future of personalized healthcare.
Mechanisms and applications of apoptosis based and molecularDrSatyabrataSahoo
The document discusses apoptosis, or programmed cell death, and strategies for targeting apoptosis for disease treatment. It notes that apoptosis is regulated by various molecules and caspase activation plays a key role. Cancer development involves evading apoptosis, so targeting apoptosis is a promising strategy. Several therapeutic agents targeting different apoptosis regulators are in clinical trials, alone or in combination with chemotherapy. Strategies include targeting caspases, death receptor signaling, or modulating other apoptosis components. Successful targeting of apoptosis has been demonstrated in experimental models and holds potential for treating various diseases.
ImMucin-2014 12 carmon et al bjh13245 (2)Leor Mann
This phase I/II study assessed the safety, immune response, and clinical effects of administering ImMucin, a MUC1 signal peptide cancer vaccine, to 15 multiple myeloma patients. Vaccination with ImMucin plus GM-CSF was well tolerated and induced robust MUC1-specific CD4+ and CD8+ T cell responses and antibody production in patients. Eleven of fifteen patients experienced stable disease or improvement for 17.5-41.3 months following vaccination. The vaccine appears to be a safe and effective way to stimulate anti-tumor immunity in multiple myeloma patients.
Immune related adevrse_events_of_iplimumabAhmed Allam
Targeted therapy refers to agents that target molecular pathways altered in cancer cells. Ipilimumab is an immune checkpoint inhibitor targeted therapy for melanoma. It can cause immune-related adverse events (irAEs) including dermatitis, diarrhea/colitis, and hepatotoxicity as the immune system attacks healthy tissue. Management of irAEs involves monitoring for symptoms, testing to rule out other causes, and administering corticosteroids to suppress the immune response. Ipilimumab also has a unique kinetic of response unlike chemotherapy.
This document summarizes various cancer immunotherapies including immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 antibodies. It discusses clinical trials of these therapies in treating cancers like melanoma, non-small cell lung cancer, and renal cancer. The trials showed improved overall survival, progression-free survival, and response rates compared to chemotherapy or standard treatments. Adverse events were manageable and responses did not depend on dose or PD-L1 expression levels. Biomarkers to predict response are still being investigated.
This will provide you the introduction about the tumor, its Anatomy & Physiology,How they are monitored?, Classification and grades of tumor, Tumor Targeting Techniques, strategies and Principles. Also provide you some examples of Marketed products.
This document discusses tumor targeting for drug delivery. It begins by defining tumors and the types of cancer. It then discusses the differences between tumor tissue and normal tissue that allow for targeted delivery. The main approaches to tumor targeting discussed are passive targeting, which exploits the enhanced permeability and retention effect, and active targeting using ligands that bind to receptors overexpressed on tumor cells. Examples are given of marketed products that use each approach. Triggered drug delivery is also covered, which releases drugs in response to the unique tumor microenvironment.
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
This document discusses drug resistant tuberculosis (TB) and provides definitions, mechanisms, factors, diagnostic tests, treatment principles and regimens for multi-drug resistant TB (MDR-TB). It defines MDR-TB as resistance to at least isoniazid and rifampin and notes management requires specialized treatment units, reliable drug susceptibility testing, and directly observed long-term combination drug regimens using second-line drugs. Acceptable regimens are outlined based on patterns of resistance to first-line drugs.
This document discusses immunotherapy strategies for metastatic renal cell carcinoma (RCC), including cytokines like interleukin-2 (IL-2) and interferon-α (IFN-α). It finds that high-dose IL-2 produces durable responses in a small percentage of selected patients, while IFN-α provides a modest survival benefit. Combining cytokines with targeted therapies may improve outcomes compared to cytokine monotherapy. Biomarkers like carbonic anhydrase IX expression and histologic subtype may help predict which patients are most likely to benefit from IL-2 therapy. Ongoing research aims to better select patients for IL-2 and explore combination therapies and novel immunotherapies to optimize treatment of metastatic RCC.
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Joseph Levy MedicReS World Congress 2013 - 2MedicReS
This document discusses challenges in designing pharmacogenomics clinical trials. It provides an overview of pharmacogenomics and different types of pharmacogenomics studies. It then discusses three common clinical trial designs - subgroups analysis design, enrichment design, and genotype-guided design - and their advantages and disadvantages. Key challenges in pharmacogenomics clinical trials include small sample sizes for subgroups, possible confounding and selection biases, and statistical power issues. Prospective clinical trials are needed to validate predictive biomarkers and assess clinical utility of genotype-guided treatments.
Bone marrow targeting strategies aim to deliver therapeutic agents specifically to the bone marrow for diseases like leukemia, multiple myeloma, and bone metastases. The presentation discusses various bone marrow targeting approaches like passive targeting using nanoparticles smaller than 150nm, macrophage-mediated targeting using surface receptors, vascular targeting using angiogenesis receptors, bone surface binding using hydroxyapatite interactions, and cell-specific targeting using receptors overexpressed on tumor cells. Case studies demonstrate that neutral nanoparticles have longer circulation and bone marrow localization compared to charged particles. Aptamer-functionalized nanoparticles can directly target leukemic cells. Overall, targeted delivery to bone marrow holds potential to improve treatment of hematological cancers and bone diseases.
Cancer immunotherapy harnesses the power of the immune system to fight cancer. Various immunotherapy approaches have been developed including vaccines, cytokines, monoclonal antibodies, and engineered T cells. Many immunotherapies have received FDA approval based on clinical trials demonstrating improved outcomes for cancer patients. New clinical trial designs are exploring immunotherapy combinations in "basket trials" that group patients by biomarkers rather than cancer type and "umbrella trials" that test multiple therapies in one study. Immunotherapy is transforming cancer treatment by activating the immune system against tumors.
This document summarizes an article from the journal Chest in 2011 about antibiotic dosing in critically ill patients with multiple organ dysfunction syndrome (MODS). The article reviews how MODS can significantly alter a patient's physiology and affect antibiotic pharmacokinetics. Specifically, MODS often leads to an increased volume of distribution and lower-than-expected drug concentrations during initial therapy. It also commonly causes decreased antibiotic clearance, which can result in drug toxicity. The article provides dosing recommendations, suggesting that initial antibiotic doses for MODS patients should account for likely increases in volume of distribution, and that maintenance doses need adjustment according to degree of organ dysfunction and drug clearance.
1) The neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammation, independently predicts tumor recurrence and mortality in patients receiving orthotopic liver transplantation for hepatocellular carcinoma.
2) Elevated pre-transplant NLR is associated with more invasive tumors and poorer tumor differentiation, and NLR may reflect immunosuppression in the host.
3) NLR could be added to current staging systems to improve patient selection and prognosis prediction for liver transplantation in hepatocellular carcinoma patients.
This document discusses newer antibiotics and their uses. It introduces several classes of newer antibiotics, including oxazolidinones (linezolid), glycolipopeptides (daptomycin), glycopeptides (telavancin), and pleuromutilins (retapamulin). These newer drugs are effective against multidrug-resistant gram-positive pathogens like MRSA and VRE. The document reviews the mechanisms of action, indications, clinical trial results, and side effects of these newer antibiotic classes.
Cancer Medicine - 2023 - Ma - Novel strategies to reverse chemoresistance in ...damodara kumaran
This document reviews novel strategies to reverse chemoresistance in colorectal cancer. It discusses using drug repurposing with nonsteroidal anti-inflammatory drugs, metformin, and other drugs. It also discusses using gene therapy with ribozymes, RNAi, CRISPR/Cas9 and other methods. Protein inhibitors targeting EFGR, S1PR2 and DNA methyltransferase are also reviewed. The use of natural compounds and new drug delivery systems with nanocarriers are discussed. Combination therapy is also mentioned as a potential strategy. Overall, the review evaluates common and novel approaches to overcome resistance and improve colorectal cancer treatment outcomes.
Antimicrobial therapy of eukaryotic parasites pdf.pptxssuserdc3441
This document summarizes challenges related to developing drugs to treat eukaryotic microbial pathogens. It discusses how eukaryotic microbes are more similar to human hosts than prokaryotic pathogens, requiring drugs to target differences. It also notes that many eukaryotic pathogens have evolved immune evasion mechanisms, increasing the impact of persistent phenotypes. Additionally, clinical diagnosis and screening for drug resistance in eukaryotic pathogens can be more difficult than for bacteria. The document concludes by stating that developing effective vaccines for prevention of eukaryotic microbial infections has generally proven challenging.
1) The document discusses new complement inhibitor drugs and their implications for clinical practice and vaccination policy. It reviews complement activation pathways and deficiencies.
2) Patients receiving complement inhibitor treatments like eculizumab are at higher risk for invasive meningococcal disease due to vaccine failures or non-vaccine serogroup infections. One case study showed IMD from a vaccine-targeted but penicillin-resistant strain in a patient on eculizumab.
3) The document recommends vaccination against meningococcal serogroups A, C, W, and Y for those with complement deficiencies from inherited or acquired causes like treatment. It also suggests continuing antibiotic prophylaxis and planning for self-treatment rescue antibiotics
Cancer Chemoprevention and Molecular Targeting Drug Delivery for CancerSukriti Singh
This document discusses cancer chemoprevention and molecular targeting for drug delivery in cancer treatment. It defines chemoprevention as using agents to reverse, suppress or prevent cancer development. Molecular targeting delivers medication selectively to target tissues to improve efficacy and reduce side effects. Various targeting strategies and carrier systems are described for achieving targeted delivery of chemopreventive and chemotherapeutic agents, including passive, active, ligand-mediated and physical targeting using nanoparticles, liposomes, dendrimers and other carriers. The advantages and challenges of targeted drug delivery systems for cancer are also summarized.
The document discusses recent advances in biosimilars and their future prospects. It begins with an abstract about a student's seminar presentation on personalized medicine and pharmacogenomics. The contents section lists topics like what biosimilars are, literature reviews on the use of targeted drugs and clinical trials, the need for and advantages of personalized medicine, and case studies on using genetic testing to target lung cancer treatments. It explores how pharmacogenomics can optimize drug responses based on a patient's genetics and discusses patents and the future of personalized healthcare.
Mechanisms and applications of apoptosis based and molecularDrSatyabrataSahoo
The document discusses apoptosis, or programmed cell death, and strategies for targeting apoptosis for disease treatment. It notes that apoptosis is regulated by various molecules and caspase activation plays a key role. Cancer development involves evading apoptosis, so targeting apoptosis is a promising strategy. Several therapeutic agents targeting different apoptosis regulators are in clinical trials, alone or in combination with chemotherapy. Strategies include targeting caspases, death receptor signaling, or modulating other apoptosis components. Successful targeting of apoptosis has been demonstrated in experimental models and holds potential for treating various diseases.
ImMucin-2014 12 carmon et al bjh13245 (2)Leor Mann
This phase I/II study assessed the safety, immune response, and clinical effects of administering ImMucin, a MUC1 signal peptide cancer vaccine, to 15 multiple myeloma patients. Vaccination with ImMucin plus GM-CSF was well tolerated and induced robust MUC1-specific CD4+ and CD8+ T cell responses and antibody production in patients. Eleven of fifteen patients experienced stable disease or improvement for 17.5-41.3 months following vaccination. The vaccine appears to be a safe and effective way to stimulate anti-tumor immunity in multiple myeloma patients.
Immune related adevrse_events_of_iplimumabAhmed Allam
Targeted therapy refers to agents that target molecular pathways altered in cancer cells. Ipilimumab is an immune checkpoint inhibitor targeted therapy for melanoma. It can cause immune-related adverse events (irAEs) including dermatitis, diarrhea/colitis, and hepatotoxicity as the immune system attacks healthy tissue. Management of irAEs involves monitoring for symptoms, testing to rule out other causes, and administering corticosteroids to suppress the immune response. Ipilimumab also has a unique kinetic of response unlike chemotherapy.
This document summarizes various cancer immunotherapies including immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 antibodies. It discusses clinical trials of these therapies in treating cancers like melanoma, non-small cell lung cancer, and renal cancer. The trials showed improved overall survival, progression-free survival, and response rates compared to chemotherapy or standard treatments. Adverse events were manageable and responses did not depend on dose or PD-L1 expression levels. Biomarkers to predict response are still being investigated.
This will provide you the introduction about the tumor, its Anatomy & Physiology,How they are monitored?, Classification and grades of tumor, Tumor Targeting Techniques, strategies and Principles. Also provide you some examples of Marketed products.
This document discusses tumor targeting for drug delivery. It begins by defining tumors and the types of cancer. It then discusses the differences between tumor tissue and normal tissue that allow for targeted delivery. The main approaches to tumor targeting discussed are passive targeting, which exploits the enhanced permeability and retention effect, and active targeting using ligands that bind to receptors overexpressed on tumor cells. Examples are given of marketed products that use each approach. Triggered drug delivery is also covered, which releases drugs in response to the unique tumor microenvironment.
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
This document discusses drug resistant tuberculosis (TB) and provides definitions, mechanisms, factors, diagnostic tests, treatment principles and regimens for multi-drug resistant TB (MDR-TB). It defines MDR-TB as resistance to at least isoniazid and rifampin and notes management requires specialized treatment units, reliable drug susceptibility testing, and directly observed long-term combination drug regimens using second-line drugs. Acceptable regimens are outlined based on patterns of resistance to first-line drugs.
This document discusses immunotherapy strategies for metastatic renal cell carcinoma (RCC), including cytokines like interleukin-2 (IL-2) and interferon-α (IFN-α). It finds that high-dose IL-2 produces durable responses in a small percentage of selected patients, while IFN-α provides a modest survival benefit. Combining cytokines with targeted therapies may improve outcomes compared to cytokine monotherapy. Biomarkers like carbonic anhydrase IX expression and histologic subtype may help predict which patients are most likely to benefit from IL-2 therapy. Ongoing research aims to better select patients for IL-2 and explore combination therapies and novel immunotherapies to optimize treatment of metastatic RCC.
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Joseph Levy MedicReS World Congress 2013 - 2MedicReS
This document discusses challenges in designing pharmacogenomics clinical trials. It provides an overview of pharmacogenomics and different types of pharmacogenomics studies. It then discusses three common clinical trial designs - subgroups analysis design, enrichment design, and genotype-guided design - and their advantages and disadvantages. Key challenges in pharmacogenomics clinical trials include small sample sizes for subgroups, possible confounding and selection biases, and statistical power issues. Prospective clinical trials are needed to validate predictive biomarkers and assess clinical utility of genotype-guided treatments.
Bone marrow targeting strategies aim to deliver therapeutic agents specifically to the bone marrow for diseases like leukemia, multiple myeloma, and bone metastases. The presentation discusses various bone marrow targeting approaches like passive targeting using nanoparticles smaller than 150nm, macrophage-mediated targeting using surface receptors, vascular targeting using angiogenesis receptors, bone surface binding using hydroxyapatite interactions, and cell-specific targeting using receptors overexpressed on tumor cells. Case studies demonstrate that neutral nanoparticles have longer circulation and bone marrow localization compared to charged particles. Aptamer-functionalized nanoparticles can directly target leukemic cells. Overall, targeted delivery to bone marrow holds potential to improve treatment of hematological cancers and bone diseases.
Cancer immunotherapy harnesses the power of the immune system to fight cancer. Various immunotherapy approaches have been developed including vaccines, cytokines, monoclonal antibodies, and engineered T cells. Many immunotherapies have received FDA approval based on clinical trials demonstrating improved outcomes for cancer patients. New clinical trial designs are exploring immunotherapy combinations in "basket trials" that group patients by biomarkers rather than cancer type and "umbrella trials" that test multiple therapies in one study. Immunotherapy is transforming cancer treatment by activating the immune system against tumors.
This document summarizes an article from the journal Chest in 2011 about antibiotic dosing in critically ill patients with multiple organ dysfunction syndrome (MODS). The article reviews how MODS can significantly alter a patient's physiology and affect antibiotic pharmacokinetics. Specifically, MODS often leads to an increased volume of distribution and lower-than-expected drug concentrations during initial therapy. It also commonly causes decreased antibiotic clearance, which can result in drug toxicity. The article provides dosing recommendations, suggesting that initial antibiotic doses for MODS patients should account for likely increases in volume of distribution, and that maintenance doses need adjustment according to degree of organ dysfunction and drug clearance.
1) The neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammation, independently predicts tumor recurrence and mortality in patients receiving orthotopic liver transplantation for hepatocellular carcinoma.
2) Elevated pre-transplant NLR is associated with more invasive tumors and poorer tumor differentiation, and NLR may reflect immunosuppression in the host.
3) NLR could be added to current staging systems to improve patient selection and prognosis prediction for liver transplantation in hepatocellular carcinoma patients.
This document discusses newer antibiotics and their uses. It introduces several classes of newer antibiotics, including oxazolidinones (linezolid), glycolipopeptides (daptomycin), glycopeptides (telavancin), and pleuromutilins (retapamulin). These newer drugs are effective against multidrug-resistant gram-positive pathogens like MRSA and VRE. The document reviews the mechanisms of action, indications, clinical trial results, and side effects of these newer antibiotic classes.
Cancer Medicine - 2023 - Ma - Novel strategies to reverse chemoresistance in ...damodara kumaran
This document reviews novel strategies to reverse chemoresistance in colorectal cancer. It discusses using drug repurposing with nonsteroidal anti-inflammatory drugs, metformin, and other drugs. It also discusses using gene therapy with ribozymes, RNAi, CRISPR/Cas9 and other methods. Protein inhibitors targeting EFGR, S1PR2 and DNA methyltransferase are also reviewed. The use of natural compounds and new drug delivery systems with nanocarriers are discussed. Combination therapy is also mentioned as a potential strategy. Overall, the review evaluates common and novel approaches to overcome resistance and improve colorectal cancer treatment outcomes.
Antimicrobial therapy of eukaryotic parasites pdf.pptxssuserdc3441
This document summarizes challenges related to developing drugs to treat eukaryotic microbial pathogens. It discusses how eukaryotic microbes are more similar to human hosts than prokaryotic pathogens, requiring drugs to target differences. It also notes that many eukaryotic pathogens have evolved immune evasion mechanisms, increasing the impact of persistent phenotypes. Additionally, clinical diagnosis and screening for drug resistance in eukaryotic pathogens can be more difficult than for bacteria. The document concludes by stating that developing effective vaccines for prevention of eukaryotic microbial infections has generally proven challenging.
1) The document discusses new complement inhibitor drugs and their implications for clinical practice and vaccination policy. It reviews complement activation pathways and deficiencies.
2) Patients receiving complement inhibitor treatments like eculizumab are at higher risk for invasive meningococcal disease due to vaccine failures or non-vaccine serogroup infections. One case study showed IMD from a vaccine-targeted but penicillin-resistant strain in a patient on eculizumab.
3) The document recommends vaccination against meningococcal serogroups A, C, W, and Y for those with complement deficiencies from inherited or acquired causes like treatment. It also suggests continuing antibiotic prophylaxis and planning for self-treatment rescue antibiotics
This case report discusses relapses in chronic bacterial prostatitis that are often related to biofilm formation. The case involves a 50-year-old man with recurrent prostatitis despite multiple courses of antibiotics. Biofilm may contribute to treatment failure by protecting bacteria from antibiotics and enabling persistence. The literature review finds that fluoroquinolone-macrolide combinations administered for 4 weeks show higher eradication rates than fluoroquinolones alone for 6 weeks. Macrolides help disrupt biofilms and have good prostate penetration. Long-term antibiotic suppression or surgical procedures may be considered for refractory cases not responding to standard treatments.
Monoclonal Antibodies As Therapeutic Agents In Oncology Anddrmisbah83
This document discusses monoclonal antibodies as therapeutic agents for cancer and antibody gene therapy. It describes how monoclonal antibodies work to target cancer cells, lists some common monoclonal antibody drugs approved for cancer treatment, and discusses potential side effects. It also introduces the concept of using antibody gene therapy as a new strategy for cancer treatment by delivering antibody genes directly to tumors using vectors like adenovirus or mesenchymal stem cells.
Pharmacogenetics and antibiotic drugs.pptxGunjitSetia1
Antibiotics have revolutionized modern medicine, saving countless lives by combatting bacterial infections.
However, the emergence of antibiotic-resistant bacteria presents a formidable challenge to global health.
Pharmacogenetics focuses on the interplay between an individual's genetic makeup and their response to drugs.
This presentation delves into the intriguing realm of pharmacogenetics within the context of antibiotic therapy, aiming to shed light on how genetic variations can influence antibiotic effectiveness and how this knowledge can be harnessed to develop more precise, personalized treatment strategies.
This document summarizes a journal presentation on the relationship between duration and life-stage of antibiotic use and the risk of cardiovascular events in women. The presentation found that longer durations of antibiotic use in middle adulthood were associated with an increased risk of cardiovascular disease later in life. Specifically, using antibiotics for 2 months or more between ages 40-59 was linked to higher risks. The risks may be due to effects of antibiotics on the microbiome and subsequent inflammation and weight gain. The conclusions were that cumulative antibiotic use during middle and older adulthood can increase cardiovascular risks for elderly women.
Tollerabilità e sicurezza delle attuali terapie biologiche per la psoriasi ne...Merqurio
This study evaluated the safety and tolerability of biological therapies for psoriasis in 103 patients in Italy over 6 years. Four biological therapies were studied: efalizumab, etanercept, infliximab, and adalimumab. Infliximab had a significantly higher rate of being discontinued due to severe adverse events compared to etanercept and efalizumab. Efalizumab and etanercept demonstrated more favorable safety profiles compared to infliximab. While more patients responded to infliximab initially, long-term tolerability was higher for efalizumab and etanercept due to their better safety profiles and compliance with therapy.
The document discusses multi-drug resistant Gram-negative pathogens and current and emerging therapeutic approaches. It provides an overview of colistin, tigecycline, and fosfomycin - discussing their mechanisms of action, pharmacokinetics, clinical efficacy, and safety. Colistin is an old antibiotic that is seeing renewed use for resistant infections. Tigecycline is used off-label for extremely drug resistant infections but has limitations. Fosfomycin has broad-spectrum activity against resistant bacteria including ESBL producers.
The document summarizes a presentation on antimicrobial drug resistance given by Dr. Manas Kr. Nath. It discusses the objectives of the presentation, which were to introduce antimicrobial drug resistance, define it, discuss its timeline and factors, mechanisms of resistance, control strategies, and conclusions. The presentation covered intrinsic and acquired resistance, genetic and biochemical mechanisms of resistance such as mutations, plasmids, conjugation, transduction, transformation, transposons, integrons, and production of antibiotic inactivating enzymes. It emphasized that antimicrobial resistance is a major global health concern.
Srishti Bhargav presented an overview of anti-protozoal drugs. Many effective drugs are toxic and drug resistance is a major challenge. New drugs are needed with novel mechanisms of action. Several drugs discussed include paromomycin for giardiasis, piperaquine for malaria, posaconazole for fungal infections, and albaconazole which is in pre-clinical trials. Developing tools to detect resistance early and rational drug use and combinations can help address the threat of resistance in protozoal diseases.
Vancomycin has historically been the mainstay for treating MRSA infections. However, its widespread use has led to problems like increased VRE and development of vancomycin resistance in some bacteria. The document reviews the appropriate use of vancomycin, noting that it is not actually nephrotoxic as previously believed. Dosing should be based on creatinine clearance rather than serum levels to avoid unnecessary changes. Overall, the review aims to optimize vancomycin use while minimizing development of resistance.
This document discusses how whole genome sequencing (WGS) of Mycobacterium tuberculosis has improved understanding of drug resistant tuberculosis (TB). WGS has identified specific mutations that cause resistance to classical and new antitubercular drugs. It has also revealed how resistance evolves within patients and spreads between patients. Clinical applications of WGS include rapid detection of drug resistance and tracking of TB outbreaks. However, challenges remain in applying WGS to improve TB control and diagnosis.
Marios Stylianou_Paper III_Antifungal application of nonantifungal drugs.Marios Stylianou
This study screened 844 drugs from two libraries against Candida albicans to identify previously unknown antifungal activities. 26 drugs showed antifungal activity, including 12 standard antifungal drugs and 7 drugs previously reported to have anti-Candida activity. The screening identified 7 additional drugs with antifungal activity: amonafide, tosedostat, megestrol acetate, melengestrol acetate, stanozolol, trifluperidol, and haloperidol. Further analysis found these 7 drugs had antifungal activity comparable to the standard antifungal drugs against multiple Candida species. The aminopeptidase inhibitor tosedostat displayed broad antifungal activity, including against Candid
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...inventionjournals
Acinetobacter baumannii (Ab) is a troublesome and increasingly problematic healthcareassociated pathogen, especially in critical care unit (ICU) and cardiovascular internal medicine (CIM). This organism has a capacity for long-term survival in the hospital environment. This study aimed to investigate the drug resistance patterns of Ab strains isolated from Thongnhat Dongnai General Hospital and the relationships between Ab isolations with clinical wards and year of patients. The antibiotic susceptibility of 279 Ab isolates for aminoglycosides, fluro-quinolons, cephalosporins, carbapenems, colistin and bactrim was determined using Kirby-Bauer disk diffusion method. The minimum inhibitor concentration (MIC) of 146 Ab isolates for Meropenem was determined using E-test method according to CLSI guide-line. A total 279 A. baumannii strains out of 1,976 positive isolates were collected from various specimens during study period. Among Ab-positive specimens, the most isolated specimen was sputum (26.6%, χ 2 =161.705 p<0.000),><0.000)><0.000),><0.000). Among 279 Ab isolated, resistance from 53.16% – 63.52% to aminoglycosides, 23.6% – 68.58% to fluroquinolons, 59.61% to 97.93% to cephalosporins, 60.27% to 80.7% to carbapenem, 10.53% to 66.48% to antibiotic combinations, 0.75% to colistin and 61.71% to bactrim. Among 146 multidrug-resistant Ab, 53.42% MICmeropenem ≥ 32 μg/ml and only 18.49% strains were susceptible to Meropenem. Due to the high antimicrobial resistance to two clinical wards (ICU and CIM) and carbapenems by disk agar diffusion test and E-test; we must focus on both a wiser use of antimicrobials and the prevention of infection. Continuous monitoring of antimicrobial susceptibility and strict adherence to infection prevention guidelines are essential to eliminate major outbreaks in the future.
ANTIMICROBIAL RESISTANCE PATTERNS AMONG ACINETOBACTER BAUMANNII ISOLATED FROM...inventionjournals
Acinetobacter baumannii (Ab) is a troublesome and increasingly problematic healthcareassociated pathogen, especially in critical care unit (ICU) and cardiovascular internal medicine (CIM). This organism has a capacity for long-term survival in the hospital environment. This study aimed to investigate the drug resistance patterns of Ab strains isolated from Thongnhat Dongnai General Hospital and the relationships between Ab isolations with clinical wards and year of patients. The antibiotic susceptibility of 279 Ab isolates for aminoglycosides, fluro-quinolons, cephalosporins, carbapenems, colistin and bactrim was determined using Kirby-Bauer disk diffusion method. The minimum inhibitor concentration (MIC) of 146 Ab isolates for Meropenem was determined using E-test method according to CLSI guide-line. A total 279 A. baumannii strains out of 1,976 positive isolates were collected from various specimens during study period. Among Ab-positive specimens, the most isolated specimen was sputum (26.6%, χ 2 =161.705 p<0.000),><0.000)><0.000),><0.000). Among 279 Ab isolated, resistance from 53.16% – 63.52% to aminoglycosides, 23.6% – 68.58% to fluroquinolons, 59.61% to 97.93% to cephalosporins, 60.27% to 80.7% to carbapenem, 10.53% to 66.48% to antibiotic combinations, 0.75% to colistin and 61.71% to bactrim. Among 146 multidrug-resistant Ab, 53.42% MICmeropenem ≥ 32 μg/ml and only 18.49% strains were susceptible to Meropenem. Due to the high antimicrobial resistance to two clinical wards (ICU and CIM) and carbapenems by disk agar diffusion test and E-test; we must focus on both a wiser use of antimicrobials and the prevention of infection. Continuous monitoring of antimicrobial susceptibility and strict adherence to infection prevention guidelines are essential to eliminate major outbreaks in the future
Immunotherapeutic drugs can be broadly classified into four types: checkpoint inhibitors, cytokines, monoclonal antibodies, and vaccines. However, immunotherapeutic drugs still have some problems, such as off-target side effects and poor pharmacokinetics.
An Impact of Biofield Treatment: Antimycobacterial Susceptibility Potential U...albertdivis
The aim was to evaluate the impact of biofield treatment modality on mycobacterial strains in relation to antimycobacterials susceptibility. Mycobacterial sensitivity was analysed using 12 B BACTEC vials on the BACTEC 460 TB machine in 39 lab isolates (sputum samples) from stored stock cultures.
Similar to 7 Years of Experience in Osteomyelitis Management in Caracas, Venezuela_Crimson Publishers (19)
The successful of pregnancy in humans and rodents occur between the interaction maternal and fetal
interface, specially involving the participation of uNK cells. This interaction involved neo angiogenesis,
placentation and presence of mediators like nitric oxide. During the pregnancy the administration of LPS
in the dams can results in necrosis, preterm birth, IUGR, miscarriage or neurological problem. Once the
uNK cells are activated, they can produce vasodilators, like NO. So, the main purpose of this study was
to evaluate if LPS cause alteration in the uNK cells in pregnant mice and if the same behaviour can be
detected by NO in the blood. Also we evaluated the effect of LPS to cause neurological injuries. To do that
we used pregnant mice on gd 10th and those was treated with LPS for different times. Uterine samples
were collected at 0.5,1,2 and 6hr after LPS treated and processed for paraffin embedding and tissue
homogenate. The samples designated for paraffin embedding was performed the Dolichos biflorus (DBA)
lectin cytochemistry and anti-iNOS immunocytochemistry. The samples designated to tissue homogenates
were processed for SDS-PAGE and Western-blot using anti-iNOS and evaluate of NO concentration. We
found after 2h LPS exposure the mice showed fever and low capacity to explore different environment.
At the same time, we found increase in the nitrate/nitrito ratio in a dose dependent manner in the uterus
after 2h LPS exposure.
Comparison of Ultrabio HIV DNA PCR and Gag Real-Time PCR Assays for Total Hiv...CrimsonpublishersCJMI
Comparison of Ultrabio HIV DNA PCR and Gag Real-Time PCR Assays for Total Hiv-1 DNA Quantification by Tuofu Zhu in Cohesive Journal of Microbiology & Infectious Disease
Disinfection of Mycotic Species Isolated from Cases of Bovine Mastitis Showin...CrimsonpublishersCJMI
Disinfection of Mycotic Species Isolated from Cases of Bovine Mastitis Showing Antifungal Resistance by Elaine Meade in Cohesive Journal of Microbiology & Infectious Disease
Computational Prediction for Antibiotics Resistance Through Machine Learning ...CrimsonpublishersCJMI
Computational Prediction for Antibiotics
Resistance Through Machine Learning and Pk/Pd
Analysis by Hyunjo Kim in Cohesive Journal of Microbiology & Infectious Disease
Growth Factors in the Human Body: A Conceptual Update_Crimson PublishersCrimsonpublishersCJMI
Growth factors are signaling molecules that stimulate cell growth, proliferation, and differentiation. They were originally discovered through their effects on cell and tissue growth in culture. Growth factors act through paracrine, autocrine, or endocrine signaling and can be divided into families based on their structure and function. Some major growth factor families include transforming growth factor beta (TGF-β) and insulin-like growth factor. Growth factors play roles in processes like wound healing but can also contribute to diseases such as cancer, diabetes, and liver fibrosis when their regulation is abnormal.
Prevalence of Intestinal Parasitic Infections among Patients Attended to Alri...CrimsonpublishersCJMI
Prevalence of Intestinal Parasitic Infections among Patients Attended to Alribat University hospital, Khartoum State, Sudan, 2017 by Mohammed HMN in Cohesive Journal of Microbiology & Infectious Disease
Epidemiology of Onychomycosis in Pernambuco, Northeastern of Brazil: Results ...CrimsonpublishersCJMI
Epidemiology of Onychomycosis in Pernambuco, Northeastern of Brazil: Results of a Laboratory-Based Survey by Gonçalves de Lima Neto in Cohesive Journal of Microbiology & Infectious Disease
Prevalence of Intestinal Parasitic Infections among Patients Attended to Alri...CrimsonpublishersCJMI
This document discusses the importance of an integrated research approach for developing microalgae fuels. It notes that interest in microalgae fuels has fluctuated with oil prices over time. While some technological advances have been made in individual stages of biomass production and processing, an integrated approach considering all stages together from strain selection to fuel conversion is needed to make the whole process economical. Each step in the process depends on and provides feedback to influence other steps. An integrated and continued research effort is required to generate realistic economic assessments for commercial scale microalgae fuel production.
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter...CrimsonpublishersCJMI
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter Retrospective Greek Study by Lamprini Gkaravela in Cohesive Journal of Microbiology & Infectious Disease
Genetic Resistance to Infectious Diseases in the Era of Personalized Medicine...CrimsonpublishersCJMI
Genetic Resistance to Infectious Diseases in the Era of Personalized Medicine by Andrei Alimov in Cohesive Journal of Microbiology & Infectious Disease
Established the Environmental Monitoring Program Indicators to Prevent Diseas...CrimsonpublishersCJMI
Established the Environmental Monitoring Program Indicators to Prevent Disease Infection and Promote Sustainable Development by Yi-Che Shih in Cohesive Journal of Microbiology & Infectious Disease
The Evaluation of the Speed-Oligo® Mycobacteria Assay for Identification of M...CrimsonpublishersCJMI
The Evaluation of the Speed-Oligo® Mycobacteria Assay for Identification of Mycobacterium spp. from Smear Positive and Negative Sputum Samples by Gülnur Tarhan in ohesive Journal of Microbiology & Infectious Disease
Molecular Study of Cutaneous Leishmaniasis Human Reservoirs and Infections in...CrimsonpublishersCJMI
Molecular Study of Cutaneous Leishmaniasis Human Reservoirs and Infections in Bastak by Houshang Jamali in Cohesive Journal of Microbiology & Infectious Disease
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com